Q-Line Biotech H1 profit slips 6% as costs rise

Q-Line Biotech Limited reported standalone profit after tax of Rs 20.22 crore for the half year ended 30 September 2026, down 6% from Rs 21.53 crore a year earlier, although revenue from operations rose 6% to Rs 152.07 crore. Higher finance costs, depreciation and tax expense outweighed the increase in revenue.

Why did Q-Line Biotech’s H1 profit fall despite revenue growth?

Q-Line Biotech’s profit fell because costs and tax increased more than the gain in revenue during the half year ended 30 September 2026. Revenue from operations increased by Rs 8.47 crore from Rs 143.60 crore in the corresponding half year ended 30 September 2025, while total expenses increased by Rs 9.67 crore to Rs 129.39 crore.

Finance costs rose to Rs 9.56 crore from Rs 8.16 crore, an increase of Rs 1.40 crore, while depreciation and amortisation rose by Rs 3.80 crore to Rs 7.88 crore. These two charges together increased by Rs 5.20 crore, compared with a Rs 2.77 crore increase in total revenue, including other income, to Rs 156.14 crore.

Profit before tax nevertheless edged up to Rs 26.75 crore from Rs 26.54 crore in the year-earlier half. Tax expense rose to Rs 6.54 crore from Rs 5.01 crore, resulting in profit after tax of Rs 20.22 crore, compared with Rs 21.53 crore in the corresponding 2025 period.

How did Q-Line Biotech’s segments contribute to H1 revenue?

Q-Line Biotech generated Rs 88.03 crore of revenue from manufacturing and Rs 64.04 crore from trading in the September 2026 half year. Manufacturing therefore supplied the larger share of the Rs 152.07 crore reported revenue from operations, ahead of the trading segment.

Manufacturing reported segment profit before finance costs and tax of Rs 52.77 crore, while trading reported Rs 17.41 crore. The combined segment result was Rs 70.18 crore, before Rs 9.56 crore of finance costs, Rs 7.88 crore of depreciation and Rs 25.99 crore of net unallocable income and expenditure adjustments.

The immediately preceding half year had higher reported revenue and profit. Revenue from operations was Rs 197.56 crore in the half year ended 31 March 2026, compared with Rs 152.07 crore in the September 2026 half, while profit after tax decreased from Rs 35.42 crore to Rs 20.22 crore; the March 2026 period included Rs 0.98 crore of extraordinary income.

Basic and diluted earnings per share were Rs 10.80 for the half year ended 30 September 2026, against Rs 13.67 in the corresponding half year ended 30 September 2025. Q-Line Biotech said the half-year earnings-per-share figure, calculated under Accounting Standard 20, Earnings Per Share, is not annualised.

What changed in Q-Line Biotech’s balance sheet by September 2026?

Q-Line Biotech’s standalone total assets increased to Rs 679.75 crore at 30 September 2026 from Rs 547.06 crore at 31 March 2026. Shareholders’ funds rose to Rs 483.32 crore from Rs 247.39 crore, including an increase in share capital to Rs 23.33 crore from Rs 16.28 crore.

Current assets increased by Rs 145.49 crore to Rs 489.30 crore. Other bank balances rose to Rs 152.28 crore from Rs 35.20 crore, and the cash-flow statement identifies Rs 107.62 crore of unutilised initial public offering proceeds placed in term deposits during the half year.

Inventories rose to Rs 107.82 crore from Rs 94.76 crore, while trade receivables increased to Rs 138.56 crore from Rs 126.91 crore. Short-term loans and advances also rose to Rs 52.78 crore from Rs 36.03 crore, showing that the increase in current assets extended beyond the term-deposit balance.

How did Q-Line Biotech’s borrowings and cash flows move?

Q-Line Biotech’s long-term borrowings declined to Rs 21.35 crore at 30 September 2026 from Rs 86.12 crore at 31 March 2026, while short-term borrowings fell to Rs 98.85 crore from Rs 126.84 crore. The cash-flow statement records repayment of Rs 64.77 crore of long-term borrowings and Rs 27.99 crore of short-term borrowings during the half year.

The company reported a net operating cash outflow of Rs 8.47 crore for the half year after net tax paid of Rs 13.01 crore. Operating profit before working-capital changes was Rs 40.33 crore, but increased inventory of Rs 13.06 crore, increased trade receivables of Rs 11.84 crore and a Rs 14.32 crore reduction in trade payables reduced cash generated from operations to Rs 4.55 crore.

Investing activities used Rs 113.19 crore, led by the Rs 107.62 crore placement of unutilised initial public offering proceeds in term deposits and Rs 8.32 crore spent on property, plant and equipment. Financing activities generated Rs 113.39 crore, including Rs 241.92 crore of proceeds from issue of share capital, partly offset by a Rs 26.21 crore cash outflow recorded as issue-related spending.

Cash and cash equivalents fell by Rs 8.27 crore to Rs 32.46 crore at 30 September 2026 from Rs 40.73 crore at 31 March 2026. The cash-flow statement was prepared using the indirect method under Accounting Standard 3, Cash Flow Statements, and separately presents term deposits within other bank balances.

What did Q-Line Biotech disclose about accounting and review?

Q-Line Biotech’s unaudited standalone results for the half year ended 30 September 2026 were reviewed by the Audit Committee and approved by the board on 12 November 2026. The statutory auditor issued an unmodified limited-review report under Regulation 33 of the Securities and Exchange Board of India Listing Obligations and Disclosure Requirements Regulations, 2015.

The results use Accounting Standards rather than Indian Accounting Standards because Q-Line Biotech is listed on the National Stock Exchange of India’s small and medium enterprises platform and is exempt from compulsory Indian Accounting Standards adoption under the cited rules. The 31 March 2026 half-year figures are balancing figures between the audited full-year numbers and unaudited year-to-date figures for the half year ended 30 September 2025.

Q-Line Biotech also said it had assessed the available information on the four Labour Codes notified by the Government of India on 21 November 2025. The company said it would provide any further accounting effect if final Central or State rules and government clarifications require it.

Conclusion

Q-Line Biotech’s September 2026 half-year result shows that a Rs 8.47 crore increase in revenue from operations did not produce higher profit after tax. Finance costs and depreciation rose by a combined Rs 5.20 crore, tax expense increased to Rs 6.54 crore, and working-capital movements contributed to an Rs 8.47 crore operating cash outflow.

The next disclosed matter to watch is the finalisation of Central and State rules and further government clarifications on the Labour Codes notified in November 2025. Q-Line Biotech has said it will assess whether those developments require an additional accounting effect in future reporting periods.